Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 35

1.

The mTOR inhibitor everolimus overcomes CXCR4-mediated resistance to histone deacetylase inhibitor panobinostat through inhibition of p21 and mitotic regulators.

Beider K, Bitner H, Voevoda-Dimenshtein V, Rosenberg E, Sirovsky Y, Magen H, Canaani J, Ostrovsky O, Shilo N, Shimoni A, Abraham M, Weiss L, Milyavsky M, Peled A, Nagler A.

Biochem Pharmacol. 2019 Oct;168:412-428. doi: 10.1016/j.bcp.2019.07.016. Epub 2019 Jul 17.

PMID:
31325448
2.

Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in Patients Age >69 Years with Acute Myelogenous Leukemia: On Behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.

Ringdén O, Boumendil A, Labopin M, Canaani J, Beelen D, Ehninger G, Niederwieser D, Finke J, Stelljes M, Gerbitz A, Ganser A, Kröger N, Kantz L, Brecht A, Savani B, Sadeghi B, Mohty M, Nagler A.

Biol Blood Marrow Transplant. 2019 Jun 7. pii: S1083-8791(19)30362-3. doi: 10.1016/j.bbmt.2019.05.037. [Epub ahead of print]

PMID:
31181255
3.

Gilteritinib induces differentiation in relapsed and refractory FLT3-mutated acute myeloid leukemia.

McMahon CM, Canaani J, Rea B, Sargent RL, Qualtieri JN, Watt CD, Morrissette JJD, Carroll M, Perl AE.

Blood Adv. 2019 May 28;3(10):1581-1585. doi: 10.1182/bloodadvances.2018029496. No abstract available.

4.

Clonal Selection with RAS Pathway Activation Mediates Secondary Clinical Resistance to Selective FLT3 Inhibition in Acute Myeloid Leukemia.

McMahon CM, Ferng T, Canaani J, Wang ES, Morrissette JJD, Eastburn DJ, Pellegrino M, Durruthy-Durruthy R, Watt CD, Asthana S, Lasater EA, DeFilippis R, Peretz CAC, McGary LHF, Deihimi S, Logan AC, Luger SM, Shah NP, Carroll M, Smith CC, Perl AE.

Cancer Discov. 2019 Aug;9(8):1050-1063. doi: 10.1158/2159-8290.CD-18-1453. Epub 2019 May 14.

PMID:
31088841
5.

Prognostic significance of recurring chromosomal abnormalities in transplanted patients with acute myeloid leukemia.

Canaani J, Labopin M, Itälä-Remes M, Blaise D, Socié G, Forcade E, Maertens J, Wu D, Malladi R, Cornelissen JJ, Huynh A, Bourhis JH, Esteve J, Mohty M, Nagler A.

Leukemia. 2019 Aug;33(8):1944-1952. doi: 10.1038/s41375-019-0439-3. Epub 2019 Mar 7.

PMID:
30846862
6.

A novel method for detecting the cellular stemness state in normal and leukemic human hematopoietic cells can predict disease outcome and drug sensitivity.

Yassin M, Aqaqe N, Yassin AA, van Galen P, Kugler E, Bernstein BE, Koren-Michowitz M, Canaani J, Nagler A, Lechman ER, Dick JE, Wienholds E, Izraeli S, Milyavsky M.

Leukemia. 2019 Aug;33(8):2061-2077. doi: 10.1038/s41375-019-0386-z. Epub 2019 Jan 31.

PMID:
30705411
7.

Trends in patient outcome over the past two decades following allogeneic stem cell transplantation for acute myeloid leukaemia: an ALWP/EBMT analysis.

Canaani J, Beohou E, Labopin M, Ghavamzadeh A, Beelen D, Hamladji RM, Niederwieser D, Volin L, Markiewicz M, Arnold R, Mufti G, Ehninger G, Socié G, Kröger N, Mohty M, Nagler A.

J Intern Med. 2019 Apr;285(4):407-418. doi: 10.1111/joim.12854. Epub 2018 Nov 16.

PMID:
30372796
8.

Minimal residual disease status predicts outcome of acute myeloid leukaemia patients undergoing T-cell replete haploidentical transplantation. An analysis from the Acute Leukaemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT).

Canaani J, Labopin M, Huang XJ, Ciceri F, Van Lint MT, Bruno B, Santarone S, Diez-Martin JL, Blaise D, Chiusolo P, Wu D, Mohty M, Nagler A.

Br J Haematol. 2018 Nov;183(3):411-420. doi: 10.1111/bjh.15540. Epub 2018 Aug 16.

PMID:
30117144
9.

Comparison of FLAMSA-based reduced intensity conditioning with treosulfan/fludarabine conditioning for patients with acute myeloid leukemia: an ALWP/EBMT analysis.

Sheth V, Labopin M, Canaani J, Volin L, Brecht A, Ganser A, Mayer J, Labussière-Wallet H, Bittenbring J, Shouval R, Savani B, Mohty M, Nagler A.

Bone Marrow Transplant. 2019 Apr;54(4):531-539. doi: 10.1038/s41409-018-0288-0. Epub 2018 Aug 7.

PMID:
30087463
10.

Identification of strong intron enhancer in the heparanase gene: effect of functional rs4693608 variant on HPSE enhancer activity in hematological and solid malignancies.

Ostrovsky O, Grushchenko-Polaq AH, Beider K, Mayorov M, Canaani J, Shimoni A, Vlodavsky I, Nagler A.

Oncogenesis. 2018 Jun 29;7(6):51. doi: 10.1038/s41389-018-0060-8.

11.

Prevention and treatment of relapse after stem cell transplantation with immunotherapy.

Gökbuget N, Canaani J, Nagler A, Bishop M, Kröger N, Avigan D.

Bone Marrow Transplant. 2018 Jun;53(6):664-672. doi: 10.1038/s41409-018-0232-3. Epub 2018 May 24. Review.

PMID:
29795427
12.

Comparable results of autologous and allogeneic haematopoietic stem cell transplantation for adults with Philadelphia-positive acute lymphoblastic leukaemia in first complete molecular remission: An analysis by the Acute Leukemia Working Party of the EBMT.

Giebel S, Labopin M, Potter M, Poiré X, Sengeloev H, Socié G, Huynh A, Afanasyev BV, Schanz U, Ringden O, Kalhs P, Beelen DW, Campos AM, Masszi T, Canaani J, Mohty M, Nagler A.

Eur J Cancer. 2018 Jun;96:73-81. doi: 10.1016/j.ejca.2018.03.018. Epub 2018 Apr 18.

PMID:
29679774
13.

T-cell replete haploidentical stem cell transplantation attenuates the prognostic impact of FLT3-ITD in acute myeloid leukemia: A report from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.

Canaani J, Labopin M, Huang XJ, Arcese W, Ciceri F, Blaise D, Irrera G, Corral LL, Bruno B, Santarone S, Van Lint MT, Vitek A, Esteve J, Mohty M, Nagler A.

Am J Hematol. 2018 Jun;93(6):736-744. doi: 10.1002/ajh.25082. Epub 2018 Mar 23.

14.

Allogeneic stem cell transplantation in acute lymphoblastic leukemia patients older than 60 years: a survey from the acute leukemia working party of EBMT.

Roth-Guepin G, Canaani J, Ruggeri A, Labopin M, Finke J, Cornelissen JJ, Delage J, Stuhler G, Rovira M, Potter M, Stadler M, Veelken H, Cahn JY, Collin M, Beguin Y, Giebel S, Nagler A, Mohty M.

Oncotarget. 2017 Dec 4;8(68):112972-112979. doi: 10.18632/oncotarget.22934. eCollection 2017 Dec 22.

15.

Dissecting the mechanisms involved in anti-human T-lymphocyte immunoglobulin (ATG)-induced tolerance in the setting of allogeneic stem cell transplantation - potential implications for graft versus host disease.

Beider K, Naor D, Voevoda V, Ostrovsky O, Bitner H, Rosenberg E, Varda-Bloom N, Marcu-Malina V, Canaani J, Danilesko I, Shimoni A, Nagler A.

Oncotarget. 2017 Oct 11;8(53):90748-90765. doi: 10.18632/oncotarget.21797. eCollection 2017 Oct 31.

16.

Donor age determines outcome in acute leukemia patients over 40 undergoing haploidentical hematopoietic cell transplantation.

Canaani J, Savani BN, Labopin M, Huang XJ, Ciceri F, Arcese W, Koc Y, Tischer J, Blaise D, Gülbas Z, Van Lint MT, Bruno B, Mohty M, Nagler A.

Am J Hematol. 2018 Feb;93(2):246-253. doi: 10.1002/ajh.24963. Epub 2017 Dec 6.

17.

Thiotepa-based conditioning versus total body irradiation as myeloablative conditioning prior to allogeneic stem cell transplantation for acute lymphoblastic leukemia: A matched-pair analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.

Eder S, Canaani J, Beohou E, Labopin M, Sanz J, Arcese W, Or R, Finke J, Cortelezzi A, Beelen D, Passweg J, Socié G, Gurman G, Aljurf M, Stelljes M, Giebel S, Mohty M, Nagler A.

Am J Hematol. 2017 Oct;92(10):997-1003. doi: 10.1002/ajh.24823. Epub 2017 Jul 19.

18.

ABO incompatibility in mismatched unrelated donor allogeneic hematopoietic cell transplantation for acute myeloid leukemia: A report from the acute leukemia working party of the EBMT.

Canaani J, Savani BN, Labopin M, Michallet M, Craddock C, Socié G, Volin L, Maertens JA, Crawley C, Blaise D, Ljungman PT, Cornelissen J, Russell N, Baron F, Gorin N, Esteve J, Ciceri F, Schmid C, Giebel S, Mohty M, Nagler A.

Am J Hematol. 2017 Aug;92(8):789-796. doi: 10.1002/ajh.24771. Epub 2017 Jun 9.

19.

Long term impact of hyperleukocytosis in newly diagnosed acute myeloid leukemia patients undergoing allogeneic stem cell transplantation: An analysis from the acute leukemia working party of the EBMT.

Canaani J, Labopin M, Socié G, Nihtinen A, Huynh A, Cornelissen J, Deconinck E, Gedde-Dahl T, Forcade E, Chevallier P, Bourhis JH, Blaise D, Mohty M, Nagler A.

Am J Hematol. 2017 Jul;92(7):653-659. doi: 10.1002/ajh.24737. Epub 2017 May 26.

20.

Impact of ABO incompatibility on patients' outcome after haploidentical hematopoietic stem cell transplantation for acute myeloid leukemia - a report from the Acute Leukemia Working Party of the EBMT.

Canaani J, Savani BN, Labopin M, Huang XJ, Ciceri F, Arcese W, Tischer J, Koc Y, Bruno B, Gülbas Z, Blaise D, Maertens J, Ehninger G, Mohty M, Nagler A.

Haematologica. 2017 Jun;102(6):1066-1074. doi: 10.3324/haematol.2016.160804. Epub 2017 Mar 2.

21.

Impact of FAB classification on predicting outcome in acute myeloid leukemia, not otherwise specified, patients undergoing allogeneic stem cell transplantation in CR1: An analysis of 1690 patients from the acute leukemia working party of EBMT.

Canaani J, Beohou E, Labopin M, Socié G, Huynh A, Volin L, Cornelissen J, Milpied N, Gedde-Dahl T, Deconinck E, Fegueux N, Blaise D, Mohty M, Nagler A.

Am J Hematol. 2017 Apr;92(4):344-350. doi: 10.1002/ajh.24640. Epub 2017 Feb 7.

22.

Established and emerging targeted therapies in the myelodysplastic syndromes.

Canaani J, Nagler A.

Expert Rev Hematol. 2016 Oct;9(10):997-1005. doi: 10.1080/17474086.2016.1233054. Epub 2016 Sep 14. Review.

PMID:
27615383
23.

Revisiting maintenance therapy in acute myeloid leukemia with novel agents.

Canaani J, Luger SM.

Curr Opin Hematol. 2016 Mar;23(2):175-80. doi: 10.1097/MOH.0000000000000223. Review.

PMID:
26766539
24.

Quizartinib elicits differential responses that correlate with karyotype and genotype of the leukemic clone.

Nybakken GE, Canaani J, Roy D, Morrissette JD, Watt CD, Shah NP, Smith CC, Bagg A, Carroll M, Perl AE.

Leukemia. 2016 Jun;30(6):1422-5. doi: 10.1038/leu.2015.320. Epub 2015 Nov 20. No abstract available.

25.

Physiologic corticosterone oscillations regulate murine hematopoietic stem/progenitor cell proliferation and CXCL12 expression by bone marrow stromal progenitors.

Kollet O, Vagima Y, D'Uva G, Golan K, Canaani J, Itkin T, Gur-Cohen S, Kalinkovich A, Caglio G, Medaglia C, Ludin A, Lapid K, Shezen E, Neufeld-Cohen A, Varol D, Chen A, Lapidot T.

Leukemia. 2013 Oct;27(10):2006-15. doi: 10.1038/leu.2013.154. Epub 2013 May 17.

PMID:
23680895
26.

Egress and Mobilization of Hematopoietic Stem and Progenitor Cells: A Dynamic Multi-facet Process.

Lapid K, Glait-Santar C, Gur-Cohen S, Canaani J, Kollet O, Lapidot T.

StemBook [Internet]. Cambridge (MA): Harvard Stem Cell Institute; 2008-.
2012 Dec 10.

27.

MicroRNA-132 modulates cholinergic signaling and inflammation in human inflammatory bowel disease.

Maharshak N, Shenhar-Tsarfaty S, Aroyo N, Orpaz N, Guberman I, Canaani J, Halpern Z, Dotan I, Berliner S, Soreq H.

Inflamm Bowel Dis. 2013 Jun;19(7):1346-53. doi: 10.1097/MIB.0b013e318281f47d.

PMID:
23598815
28.

Paradoxical immune reconstitution inflammatory syndrome associated with rituximab-containing regimen in a patient with lymphoma.

Canaani J, Amit S, Ben-Ezra J, Cohen Pour M, Sarid N, Lerman H, Perry C, Polliack A, Naparstek E, Herishanu Y.

J Clin Oncol. 2013 Apr 10;31(11):e178-80. doi: 10.1200/JCO.2012.43.6188. Epub 2013 Feb 25. No abstract available.

PMID:
23439758
29.

Acute myeloid leukemia with 11q23/MLL rearrangement after 'FCR' regimen for chronic lymphocytic leukemia.

Sarid N, Eshel R, Rothman R, Shpringer M, Perry C, Solar I, Dezorella N, Gepstein L, Canaani J, Naparstek E, Polliack A, Herishanu Y.

Eur J Haematol. 2012 Nov;89(5):430-1. doi: 10.1111/ejh.12001. Epub 2012 Aug 24. No abstract available.

PMID:
22816611
30.

FGF-2 expands murine hematopoietic stem and progenitor cells via proliferation of stromal cells, c-Kit activation, and CXCL12 down-regulation.

Itkin T, Ludin A, Gradus B, Gur-Cohen S, Kalinkovich A, Schajnovitz A, Ovadya Y, Kollet O, Canaani J, Shezen E, Coffin DJ, Enikolopov GN, Berg T, Piacibello W, Hornstein E, Lapidot T.

Blood. 2012 Aug 30;120(9):1843-55. doi: 10.1182/blood-2011-11-394692. Epub 2012 May 29.

31.

Regulatory cross talks of bone cells, hematopoietic stem cells and the nervous system maintain hematopoiesis.

Kollet O, Canaani J, Kalinkovich A, Lapidot T.

Inflamm Allergy Drug Targets. 2012 Jun;11(3):170-80. Review.

PMID:
22280241
32.

Predictive parameters for a diagnostic bone marrow biopsy specimen in the work-up of fever of unknown origin.

Ben-Baruch S, Canaani J, Braunstein R, Perry C, Ben-Ezra J, Polliack A, Naparstek E, Herishanu Y.

Mayo Clin Proc. 2012 Feb;87(2):136-42. doi: 10.1016/j.mayocp.2011.08.002. Epub 2012 Jan 9.

33.

Neural regulation of bone, marrow, and the microenvironment.

Canaani J, Kollet O, Lapidot T.

Front Biosci (Schol Ed). 2011 Jun 1;3:1021-31. Review.

PMID:
21622251
34.

Comparative analysis of Bayer wide-range C-reactive protein (wr-CRP) and the Dade-Behring high sensitivity C-reactive protein (hs-CRP) in patients with inflammatory bowel disease.

Maharshak N, Arbel Y, Gal-Oz A, Rogowski O, Shapira I, Berliner S, Vered Y, Canaani J, Dotan I.

J Dig Dis. 2008 Aug;9(3):140-3.

PMID:
18956591
35.

Heparanase expression increases throughout the endometrial hyperplasia-cancer sequence.

Canaani J, Ilan N, Back S, Gutman G, Vlodavsky I, Grisaru D.

Int J Gynaecol Obstet. 2008 May;101(2):166-71. doi: 10.1016/j.ijgo.2007.10.019. Epub 2008 Jan 24.

PMID:
18221741

Supplemental Content

Loading ...
Support Center